Raymond J. Whitaker

Sequenom, Inc. engages in the provision of early patient management information. It develops and commercializes molecular diagnostic testing services that serve women's health and oncology markets. The company was founded by Hubert Koester and Charles R. Cantor in October 09, 1996 and is headquartered in Burlington, NC.

Kosan Biosciences, Inc. develops drugs for cancer therapeutics. The company was founded in 1995 and is headquartered in New York, NY.

Xenogen Corp. provides real time in-vivo imaging services and genetic modification technologies. Its products and technologies include an imaging system, software, and biological materials. Its solutions are designed to improve discovery and pre-clinical research in multiple therapeutic areas. The company was founded by Pamela Reilly Contag and Christopher H. Contag in 1995 and is headquartered in Alameda, CA.

Hypnion, Inc. discovered and developed neuroscience drugs. It focused on the development of novel therapeutics for the treatment of central nervous system disorders to serve the underserved markets of sleep and wake-alertness disorders and circadian rhythm abnormalities. The company was founded in 2000 and was headquartered in Lexington, MA.

Part of Brightcom Group Ltd., WiseWire Corp. is a company that provides search software allowing users to perform customized searches. The company is based in Pittsburgh, PA. WiseWire was acquired by Lycos, Inc., part of Brightcom Group Ltd. from August 16, 2010 on April 30, 1998 for $22.95 million. The company was founded by Ken Lang.

Memory Pharmaceuticals Corp. develops pharmaceutical products for the treatment of debilitating central nervous system (CNS) disorders such as Alzheimer's disease and schizophrenia. The company was founded by Axel Unterbeck in 1998 and is headquartered in Montvale, NJ.

Avalon Pharmaceuticals, Inc. was a biopharmaceutical company focused on the discovery, development and commercialization of cancer therapeutics. The company was founded in November 1999 and headquartered in Germantown, MD.

Melinta Subsidiary Corp. develops and markets pharmaceutical products for the treatment of life-threatening infections. It also develops novel classes of antibiotics to treat the multi- and extremely-drug-resistant pathogens for which there are few to no options, known collectively as ESKAPE pathogens. The company was founded by John N. Abelson, Harry F. Noller, Susan Froshauer, Harry H. Penner, Jr., William L. Jorgensen, Thomas A. Steitz, and Peter Moore in October 2000 and is headquartered in New Haven, CT.